Siwon Kim

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Synthesis and Evaluation of Serinolamide Derivatives as Sphingosine-1-Phosphate-1 (S1P1) Receptor Agonists.

Synthesis and Evaluation of Serinolamide Derivatives as Sphingosine-1-Phosphate-1 (S1P1) Receptor Agonists.

Journal: Molecules (Basel, Switzerland)

Published: April 04, 2022

Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain.

Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: February 22, 2022

Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis.

Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis.

Journal: Journal of medicinal chemistry

Published: January 25, 2022

Optimization and Evaluation of Novel Antifungal Agents for the Treatment of Fungal Infection.

Optimization and Evaluation of Novel Antifungal Agents for the Treatment of Fungal Infection.

Journal: Journal of medicinal chemistry

Published: October 18, 2021

KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson's Disease.

KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson's Disease.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: July 24, 2021

Development and optimization of halogenated vinyl sulfones as Nrf2 activators for the treatment of Parkinson's disease.

Development and optimization of halogenated vinyl sulfones as Nrf2 activators for the treatment of Parkinson's disease.

Journal: European journal of medicinal chemistry

Published: September 07, 2020

Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson's disease animal model.

Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson's disease animal model.

Journal: Neuropharmacology

Published: September 17, 2019

Discovery of Novel Biased Opioid Receptor Ligands through Structure-Based Pharmacophore Virtual Screening and Experiment.

Discovery of Novel Biased Opioid Receptor Ligands through Structure-Based Pharmacophore Virtual Screening and Experiment.

Journal: ChemMedChem

Published: July 13, 2019

Optimization of Vinyl Sulfone Derivatives as Potent Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators for Parkinson's Disease Therapy.

Optimization of Vinyl Sulfone Derivatives as Potent Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators for Parkinson's Disease Therapy.

Journal: Journal of medicinal chemistry

Published: December 13, 2018

Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease.

Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease.

Journal: Science advances

Published: August 07, 2018

Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.

Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.

Journal: Bioorganic & medicinal chemistry

Published: October 30, 2017

Showing 1-11 of 11

Last Updated: 09/26/2026